Clinical Advisory Board
Dynamix is committed to state of the art drug development, employing the latest approaches in clinical drug development, including pharmacogenomics and personalized medicine. Dynamix Clinical Advisory Board plays a key role in advising the company's clinical programs and overseeing the clinical development process. Members of our Clinical Advisory Board are:
|Philip Schein, MD||Prof. Philip Schein is a Visiting Professor in Cancer Pharmacology, University of Oxford and President of The Schein Group, which provides consultative services to the biotech and pharmaceutical industries. Dr. Schein served as a Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch, National Cancer Institute. At Georgetown University School of Medicine in Washington, DC, he served as Professor of Medicine and Pharmacology, Chief of Medical Oncology and Scientific Director of the Vincent T. Lombardi Cancer Research Center. Subsequently he served as Vice President of Worldwide Clinical Research and Development, and Director of the Laboratory of Molecular Oncology, SmithKline & French Laboratories. In 1987 Dr. Schein founded U.S. Bioscience, a publically-traded pharmaceutical company focused on cancer and AIDS, and while serving as Chairman and CEO took three products, Ethyol®, Hexalen® and Neutrexin®, through development and regulatory approval in the US, Europe, Canada and other countries.
Dr. Schein has held major positions in the field of Medical Oncology. He has served as President of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. He has also served as co-Chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research.
He has authored over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents. He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA. He has been awarded an Honorary Doctor of Science degree from Rutgers University and a Doctorate Honoris Causa from the National University of Rosario, Argentina.
|Ofer Shpilberg, MD, MPH||Prof. Shpilberg is the head of the Department of Hematology at Davidoff Cancer Center, Rabin Medical Center, Israel and an Associate Professor of Hematology at Sackler Faculty of Medicine, Tel-Aviv University , Israel. He also serves as the President of the International Society of Hematology and as the President of the Israeli Society of Hematology and Blood Transfusion. Prof. Shpilberg serves as a national principal investigator on numerous international clinical trials in lymphoma and multiple myeloma and active member in a number of professional societies, including the European Hematology Association. Prof. Ofer Shpilberg received his medical degree in 1981 from Ben-Gurion University, Israel, and has earned an MPH degree from the Graduate School of Public Health at the University of Pittsburgh, PA, USA. He completed his internal medicine residency and hematology fellowship at Sheba Medical Center, Israel. His research interests have focused on the epidemiological aspects of lymphoma, leukemia and multiple myeloma, including ecological and analytic studies looking for new potential risk factors as well as systematic reviews and meta-analyses of randomized clinical trials dealing with evidence-based issues while analyzing established and new end-points of clinical trials. Prof. Shpilberg has published more than 140 peer-reviewed articles in most of the leading hematology, oncology and epidemiology journals.|
|Eyal Gottlieb, PhD||Prof. Gottlieb is a Professor of Molecular Cell Biology at the University of Glasgow and a Research Group Leader at the Beatson Institute for Cancer Research in Glasgow. Prof. Gottlieb's studies focus on cancer metabolism, combining analytic and organic chemistry with basic cancer research to explore new potential clinical approaches for cancer treatment. Prof. Gottlieb graduated from The Hebrew University of Jerusalem, Israel, and obtained a MSc and a PhD from the Weizmann Institute of Science, Rehovot, Israel where he studied the role of the p53 transcription factor and tumor suppressor in apoptosis. Following that, he moved to the University of Chicago as an EMBO Postdoctoral Fellow focusing on the metabolic roles of mitochondrial in apoptosis. He then became a Special Fellow of the Leukemia and Lymphoma Society at the University of Pennsylvania, focusing on cancer metabolism, before moving to the Beatson Institute for Cancer Research in Glasgow.